The Food and Drug Administration announced on Monday that it has granted clearance for a new blood test designed to aid in the detection of Alzheimer’s disease. The test, called Elecsys pTau217, was developed by Swiss‑based Roche in partnership with Eli Lilly and is intended for use in adults 55 years of age and older who are experiencing cognitive decline.
How the test works
Elecsys pTau217 measures the level of a specific protein fragment, pTau217, in a patient’s blood. Elevated levels of this biomarker are associated with the amyloid plaques and neurofibrillary tangles that characterize Alzheimer’s disease. While the test is not meant to serve as a stand‑alone diagnostic tool, Roche says the results can be combined with other clinical information—such as neurological exams, imaging studies, and patient history—to give physicians a clearer picture of whether Alzheimer’s‑related brain changes are likely present.
Potential impact on diagnosis
Current diagnostic methods for Alzheimer’s often rely on positron emission tomography (PET) scans or analysis of cerebrospinal fluid obtained via lumbar puncture. Both approaches can be costly, invasive, and limited to specialized centers. By contrast, a blood test can be performed in a standard laboratory setting, potentially expanding access to earlier detection for a broader segment of the population.
Roche notes that the Elecsys pTau217 assay can be run on more than 4,500 of its laboratory analyzers already installed across the United States. This existing infrastructure could help bring the test to many hospitals, clinics, and independent labs without the need for new equipment.
Industry response
Labcorp and Quest Diagnostics, two of the nation’s largest clinical laboratory networks, have each said they plan to offer the test through their own service lines. Their involvement could further increase the geographic reach of the assay, making it available in both urban and rural settings.
Roche has not disclosed the price of the test, but analysts expect it to be priced lower than PET imaging and cerebrospinal‑fluid analysis, which can run into several thousand dollars per patient.
Regulatory background
The FDA clearance follows a European Union approval granted in May of this year. The Elecsys pTau217 test joins Fujirebio’s Lumipulse, which became the first blood test cleared by the FDA for Alzheimer’s assessment in 2025. The growing pipeline of blood‑based diagnostics reflects a broader industry push to simplify early detection of neurodegenerative diseases.
What patients and doctors should know
Physicians are advised to interpret Elecsys pTau217 results alongside other clinical data. The test is not intended to replace comprehensive neurological evaluation, but rather to serve as an additional tool that may prompt earlier intervention, enrollment in clinical trials, or more focused monitoring.
Patients interested in the test should discuss it with their primary care provider or a neurologist to determine whether it is appropriate for their specific situation.
Looking ahead
The clearance of this blood test underscores a shift toward less invasive, more accessible diagnostic options for Alzheimer’s disease. As more laboratories adopt the technology, the hope is that earlier identification will lead to timely treatment and better outcomes for patients and families affected by this progressive condition.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
